Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease

Clinical and Translational Gastroenterology

Volumn 3, Issue , 2012, Pages

  Cayatte, Corinne ^a,d   Joyce Shaikh, Barbara ^a   Vega, Felix ^a   Boniface, Katia ^a   Grein, Jeffrey ^a   Murphy, Erin ^a   Blumenschein, Wendy M ^a   Chen, Smiley ^a   Malinao, Maria Christina ^a   Basham, Beth ^a   Pierce, Robert H ^a   Bowman, Edward P ^a   McKenzie, Brent S ^a   Elson, Charles O ^b   Faubion, William A ^c   Malefyt, Rene De Waal ^a   Kastelein, Robert A ^a   Cua, Daniel ^a   McClanahan, Terrill K ^a   Beaumont, Maribel ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b University of Alabama at Birmingham   (United States)

^c MAYO CLINIC   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CELL PROTEIN; DELETED IN MALIGNANT TUMOR 1 PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23 RECEPTOR MONOCLONAL ANTIBODY; INTERLEUKIN 23P19 MONOCLONAL ANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PANCREATITIS ASSOCIATED PROTEIN; REGENERATING PROTEIN 3BETA; REGENERATING PROTEIN 3GAMMA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON LAVAGE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; EPITHELIUM CELL; FECES ANALYSIS; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84861872216     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.2     Document Type: Article

References (46)

1. Maloy KJ. The interleukin-23/interleukin-17 axis in intestinal inflammation. J Intern Med 2008; 263: 584-590. (Pubitemid 351678587)
2. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
3. Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708. (Pubitemid 34556153)
4. Yen D, Cheung J, Scheerens H et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
5. Chen Y, Langrish CL, McKenzie B et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-1326.
6. Elson CO, Cong Y, Weaver CT et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-2370. (Pubitemid 46890867)
7. Hue S, Ahern P, Buonocore S et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483. (Pubitemid 44664617)
8. Uhlig HH, McKenzie BS, Hue S et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25: 309-318.
9. Schmidt C, Giese T, Ludwig B et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 16-23. (Pubitemid 40340252)
10. Kobayashi T, Okamoto S, Hisamatsu T et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008; 57: 1682-1689.
11. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463. (Pubitemid 44871953)
12. Pidasheva S, Trifari S, Phillips A et al. Functional Studies on the IBD Susceptibility Gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One 2011; 6: e25038.
13. Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and antiinterleukin-17A therapy. Curr Opin Infect Dis 2006; 19: 245-252. (Pubitemid 43740362)
14. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83: 227-230.
15. Rolink A, Melchers F, Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996; 5: 319-330. (Pubitemid 26366755)
16. Cong Y, Weaver CT, Lazenby A, Elson CO. Colitis induced by enteric bacterial antigenspecific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol 2000; 165: 2173-2182. (Pubitemid 30643167)
17. Wilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957. (Pubitemid 47300009)
18. Bhat VB, Choi MH, Wishnok JS, Tannenbaum SR. Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res 2005; 4: 1814-1825.
19. von Roon AC, Karamountzos L, Purkayastha S et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-813.
20. Ouyang W, Valdez P. IL-22 in mucosal immunity. Mucosal Immunol 2008; 1: 335-338.
21. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-448. (Pubitemid 27204920)
22. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377. (Pubitemid 351320845)
23. Kwon JH, Keates S, Bassani L et al. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut 2002; 51: 818-826. (Pubitemid 35408603)
24. Caruso R, Fina D, Peluso I et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007; 132: 166-175. (Pubitemid 46108732)
25. Dambacher J, Beigel F, Zitzmann K et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009; 58: 1207-1217.
26. Leach ST, Yang Z, Messina I et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 21; 2007: 1-11.
27. de Jong YP, Abadia-Molina AC, Satoskar AR et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2001; 2: 1061-1066. (Pubitemid 33069502)
28. Gironella M, Iovanna JL, Sans M et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 2005; 54: 1244-1253. (Pubitemid 41192482)
29. Andoh A, Zhang Z, Inatomi O et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129: 969-984. (Pubitemid 41242688)
30. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70. (Pubitemid 36020767)
31. Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827-G838.
32. Schmechel S, Konrad A, Diegelmann J et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008; 14: 204-212. (Pubitemid 351288041)
33. Holtta V, Klemetti P, Sipponen T et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008; 14: 1175-1184.
34. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37. (Pubitemid 46021248)
35. Ogawa H, Fukushima K, Naito H et al. Increased expression of HIP/PAP and regenerating gene III in human inflammatory bowel disease and a murine bacterial reconstitution model. Inflamm Bowel Dis 2003; 9: 162-170. (Pubitemid 36592446)
36. Moucadel V, Soubeyran P, Vasseur S et al. Cdx1 promotes cellular growth of epithelial intestinal cells through induction of the secretory protein PAP I. Eur J Cell Biol 2001; 80: 156-163. (Pubitemid 32175501)
37. Zheng Y, Valdez PA, Danilenko DM et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14: 282-289. (Pubitemid 351347912)
38. Pickert G, Neufert C, Leppkes M et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206: 1465-1472.
39. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-962.
40. Schmidt-Ott KM, Mori K, Li JY et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-413. (Pubitemid 46193306)
41. Csillag C, Nielsen OH, Vainer B et al. Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet-derived 1 alpha in Crohn's disease. Scand J Gastroenterol 2007; 42: 454-463. (Pubitemid 46569390)
42. Galamb O, Gyorffy B, Sipos F et al. Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis Markers 2008; 25: 1-16.
43. Rosenstiel P, Sina C, End C et al. Regulation of DMBT1 via NOD2 and TLR4 in intestinal epithelial cells modulates bacterial recognition and invasion. J Immunol 2007; 178: 8203-8211. (Pubitemid 46898093)
44. Renner M, Bergmann G, Krebs I et al. DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn's disease. Gastroenterology 2007; 133: 1499-1509. (Pubitemid 350029738)
45. Metz CN, Bucala R. Role of macrophage migration inhibitory factor in the regulation of the immune response. Adv Immunol 1997; 66: 197-223. (Pubitemid 127702123)
46. Kaser A, Ludwiczek O, Holzmann S et al. Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol 2004; 24: 74-85. (Pubitemid 38375798)